期刊
FUTURE ONCOLOGY
卷 16, 期 29, 页码 2273-2282出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0026
关键词
brentuximab vedotin; CD30; classical Hodgkin lymphoma; stage III or IV classical Hodgkin lymphoma
类别
Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is US FDA approved for treatment of classic Hodgkin lymphoma (cHL) after progression or relapse of at least two prior lines of chemotherapy or autologous stem cell transplantation, as consolidation therapy after autologous stem cell transplantation for high-risk patients and as a front-line therapy for previously untreated, advanced-stage cHL in combination with chemotherapy. BV is a well-tolerated treatment in previously heavily pretreated relapsed/refractory cHL and in treatment-naive patients. BV use, in combination with other antineoplastic agents for cHL, is under investigation in multiple prospective clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据